4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) (4D pharma PLC (AIM:DDDD, NASDAQ:LBPS), 4D pharma PLC (AIM:DDDD, NASDAQ:LBPS)) Duncan Peyton joins Proactive's Katie Pilbeam to talk about their live biotherapeutic for asthma showing ‘promising’ signs of clinical activity in the very initial stages of the clinical trial process.
He says they're 'really pleased with what we're seeing', part A of the phase I/II study was designed to assess the safety and tolerability of MRx-4DP0004 – and did so. No serious adverse events were reported.
Having detected the signs of clinical activity, 4D will push into Part B of the evaluation, which will recruit 90 asthma sufferers to assess further the potential efficacy of the drug.